The cannabis-mind connection: a clinician’s perspective on mental health practice, harm reduction, and racial equity
Paulette S. Smith, Leah Sera
Journal of Cannabis Research November 22, 2025 DOI: 10.1186/s42238-025-00360-1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Cannabis |
| Key points | Argues that clinicians should treat cannabis use as a valid subject of clinical conversation using a harm reduction, person-centered approach—acknowledging use without judgment, exploring patients' intentions, and supporting informed decisions—rather than abstinence-only models. The authors contend that stigma, limited training, and the racialized legacy of prohibition, which has disproportionately harmed Black and Brown communities, impede disclosure and trust, and that cultural humility is needed to counter these barriers. |
Abstract
Abstract:
Background: Cannabis is increasingly part of the mental health landscape, yet clinical practice has not kept pace with patient use. Many individuals rely on cannabis for anxiety, trauma, and mood concerns, often without professional guidance. Persistent stigma, limited training, and the racialized legacy of prohibition create barriers that prevent open dialogue in therapy and undermine patient trust. Main body: This perspective highlights the disconnect between patient experiences and clinical engagement with cannabis. Drawing on historical context, clinical insight, and emerging evidence, it considers how systemic inequities and professional discomfort shape current practice. Black and Brown communities have borne disproportionate harms from cannabis criminalization, influencing how cannabis use is perceived and discussed within care settings. A harm reduction and person-centered approach provides a framework for clinicians to engage with patients in a more ethical and effective manner. This includes acknowledging cannabis use without judgment, exploring patients’ intentions and experiences, and supporting informed decisions about risks and benefits. Cultural humility and awareness of cannabis’s historical and therapeutic roles are essential to counteracting stigma and building safety in the therapeutic relationship. By moving beyond abstinence-only models, clinicians can foster transparency and trust while respecting patient autonomy.
Conclusion: Clinicians need not endorse cannabis to engage meaningfully with patients. What is required is openness, informed practice, and recognition of the structural forces that shape patient behavior and disclosure. Approaching cannabis use as a valid subject of clinical conversation advances justice-oriented care and creates opportunities for more responsive and inclusive mental health practice.
Citations in the library
Cites 5
- History of cannabis and the endocannabinoid system Dialogues in Clinical Neuroscience September 1, 2020
- Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis The Lancet Psychiatry October 28, 2019
- Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clinical drug investigation August 2014
- PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. Journal of Psychoactive Drugs 2014
- History of cannabis as a medicine: a review. Revista Brasileira de Psiquiatria June 1, 2006